Objective:
Report updated phase 1/2 LUCE-1 trial findings for AAVantgarde Bio’s gene therapy program for Usher syndrome type 1B.
Approach:
- Study: The company reported results from its phase 1/2 study of dual AAV DNA-splicing technology for retinitis pigmentosa caused by MYO7A mutations.
- Participants: Fifteen participants had been treated.
Key Findings:
- No serious adverse events or dose-limiting toxicities had been observed; no participants had withdrawn.
- The company reported that immunosuppression was working well.
- Early efficacy signals included improvements in best-corrected visual acuity (BCVA) and low-luminance visual acuity (LLVA), including gains of at least 3 lines in LLVA.
Interpretation:
AAVantgarde described the results as promising and said it was looking to develop the Usher syndrome program in phase 3.
Limitations:
- The report provides no detailed trial methods, follow-up duration, participant characteristics, or numerical BCVA results.
- The findings are company-reported early results from a phase 1/2 study.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







